Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

BGMA

Sanofi reception

EASD 2013: Sanofi prepared for biosimilar threat to Lantus

Next generation insulin U300 set to launch at time of patent expiration

- PMLiVE

Bioclusters benefit from pharma shake-up

Sweeping job cuts at Europe’s largest drugmakers in recent years have spread gloom through the pharma sector, but the release of talent is helping to drive the development of bioclusters

- PMLiVE

Generics industry pressures FDA over biosimilar naming standards

GPhA says biosimilars should carry same name as branded biologic medicines

UK flag

UK government ‘must push for clinical trial transparency’

MP committee calls for publication of results from clinical trials using NHS treatments

- PMLiVE

UK to improve commercial viability of antibiotic research

Government unveils new research incentives as part of antimicrobial resistance strategy

EU flag

First biosimilar mAb gets the nod in EU

Approval for Hospira's version of J&J's Remicade has global implications

- PMLiVE

Baxter taps Coherus for Enbrel biosimilar

Deal to develop copy of Amgen and Pfizer's arthritis and psoriasis is worth up to $246m

- PMLiVE

UK market access: The importance of a local value story

Meeting the needs of the health service’s new stakeholders

UK flag

UK sets aside £124m for health research projects

National Institute for Health Research to aims to revolutionise care

- PMLiVE

Boehringer’s first cancer drug leads EMA recommendations

Afatinib recommended for lung cancer under brand name Giotrif

UK flag

London plans ‘Med City’ to boost UK life sciences sector

£1.1m investment will bring London, Oxford and Cambridge together in 'golden triangle' of research

- PMLiVE

Lonza ends biosimilars deal with Teva

Chemical firm cuts losses after four-year development deal

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links